Imigran

Sumatriptan succinate, the active ingredient in Imigran, is a Triptan presented as an oral tablet for oral administration. It is prescribed for the acute treatment of migraine attacks, including migraine with aura, and is intended for use in adult patients experiencing moderate to severe migraine symptoms.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards and regulatory compliance. The company ensures reliable logistics, appropriate documentation, and support for import and distribution across multiple regions.

Imigran is a Triptan that acts on the migraine pathway to relieve acute headache episodes.

Migraine attacks (with or without aura): rapid relief of headache and associated nausea or photophobia. Migraine with aura: reduction of visual and sensory disturbances accompanying the headache. Acute episodic migraine: short‑term control of single migraine episodes without preventive therapy.

Imigran may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in the face or extremities - Flushing or warmth sensation - Nausea or abdominal discomfort - Dizziness or light‑headedness - Drowsiness or fatigue

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with other serotonergic agents - Anaphylactic or severe allergic reactions - Stroke or transient ischemic attack - Severe arrhythmias or cardiac arrest

Before prescribing Imigran, clinicians should evaluate patient-specific risk factors.

Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease. Serotonergic drug review: assess risk of serotonin syndrome when combined with SSRIs, SNRIs or MAO inhibitors. Age considerations: use caution in elderly patients due to potential cardiovascular sensitivity. Pregnancy and lactation: evaluate benefits versus risks as safety data are limited. Drug interaction check: review all concomitant medications for possible interactions. Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Imigran can interact with several medication classes; careful assessment is required.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - Strong serotonergic agents (e.g., SSRIs, SNRIs, TCAs) when combined may precipitate serotonin toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible reduction in blood pressure control. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Oral contraceptives: monitor for enhanced migraine frequency or severity.